Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020722 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00020722 is a Phase 2 study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 7 participants.
The verdict
NCT00020722, a Phase 2 study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation plus biological therapy may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy followed by peripheral stem cell transplantation plus biological therapy works in treating women with stage IV breast cancer.
Interventions
- PROCEDURE Leukapheresis
- BIOLOGICAL therapeutic autologous lymphocytes
- DRUG Ifosfamide, carboplatin, and etoposide (ICE) regimen
- DRUG Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
- PROCEDURE peripheral blood stem cell transplantation (PBSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020722
The ClinicalTrials.gov registry entry for NCT00020722 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Leukapheresis is the first listed.
NCT00020722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020722 about?
NCT00020722 is a clinical study titled "Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation plus biological therapy may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. ...
What is the current status of trial NCT00020722?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00020722?
The interventions under investigation include: Leukapheresis (PROCEDURE), therapeutic autologous lymphocytes (BIOLOGICAL), Ifosfamide, carboplatin, and etoposide (ICE) regimen (DRUG), Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC) (DRUG), peripheral blood stem cell transplantation (PBSCT) (PROCEDURE).
Who is sponsoring clinical trial NCT00020722?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.